Compare Amgen, Inc. (AMGN) vs ProShares Ultra Bloomberg Natural Gas ETF (BOIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ProShares Ultra Bloomberg Natural Gas ETF — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while ProShares Ultra Bloomberg Natural Gas ETF trades at $22.13. The key difference: Amgen, Inc. pays a 2.77% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | BOIL | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $98.62 |
52-Week Low | $271.18 | $22.68 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BOIL trades at $22.68, down 4.22% in the past 24 hours amid a bearish technical outlook with moving averages signaling strong selling pressure. The stock recently underwent a 1:2 split on May 28, 2026. Key support lies at $21, with resistance at $25. Recent news highlights shareholder meeting results and natural gas market volatility influencing sentiment.
Outlook remains cautious due to weak technicals and external commodity pressures. Investment opportunities hinge on natural gas price rebounds, but risks include sustained bearish trends and energy market fluctuations. Investors should weigh technical recovery signals against fundamental exposure to volatile energy sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →
